Polymixin B

Polymixin B Market Outlook

The global Polymixin B market is anticipated to reach USD 1.5 billion by 2035, registering a compound annual growth rate (CAGR) of approximately 5.2% during the forecast period from 2025 to 2035. This projected growth is significantly driven by the increasing prevalence of multi-drug resistant bacterial infections, which has led to a heightened demand for effective antibiotic treatments such as Polymixin B. Furthermore, the rising awareness regarding infection control in healthcare settings and the expansion of healthcare facilities globally contribute to the market's expansion. Advances in pharmaceutical formulations and the development of patient-friendly delivery systems are anticipated to create additional avenues for market growth. In addition, the ongoing research and development activities aimed at improving the efficacy and safety profile of Polymixin B formulations are likely to enhance market dynamics. As healthcare providers seek reliable solutions to combat antibiotic resistance, the Polymixin B market is poised for sustained growth.

Growth Factor of the Market

The growth of the Polymixin B market is primarily propelled by the alarming increase in antibiotic-resistant infections, which necessitate the need for alternative treatment options such as Polymixin B. Moreover, the growing geriatric population, which is more susceptible to infections, contributes significantly to the demand for effective antibiotics. Additionally, continuous advancements in medical research and technology are facilitating the development of innovative Polymixin B formulations, thereby expanding their therapeutic applications. The rising healthcare expenditure, particularly in developing regions, is also a crucial factor, as it allows for better access to essential medications and treatment protocols. Furthermore, the expansion of distribution channels, including online pharmacies, is making Polymixin B products more accessible to healthcare professionals and patients alike. All these factors combined are expected to drive robust growth in the Polymixin B market over the coming years.

Key Highlights of the Market

• Growing demand for Polymixin B due to rising antibiotic resistance.
• Increased healthcare expenditure enhancing access to medications.
• Expansion of distribution channels including online pharmacies.
• Continuous R&D leading to improved formulations and delivery systems.
• High prevalence of infections, particularly in geriatric populations.

By Product Type

Injection :

Injection is the predominant product type in the Polymixin B market, accounting for a significant share due to its direct administration into the bloodstream, ensuring rapid therapeutic effects. This mode of delivery is critically important in hospital settings, particularly for patients diagnosed with severe infections caused by multidrug-resistant organisms. The injectable form of Polymixin B allows for precise dosing and rapid onset of action, making it a preferred choice among healthcare professionals. Furthermore, advancements in injection technologies, such as the development of pre-filled syringes and auto-injectors, are enhancing patient compliance and overall treatment efficacy. As healthcare providers continue to prioritize effective treatment strategies for serious infections, the injectable segment is likely to sustain robust growth in the market.

Ointment :

The ointment segment is witnessing increased adoption in the Polymixin B market, primarily due to its effectiveness in treating localized infections, particularly skin infections. This formulation provides a protective barrier over the affected area while delivering the antibiotic directly where it is needed most. The ease of application and the patient-friendly nature of ointments contribute to their growing popularity. Moreover, the increasing prevalence of skin infections, including those caused by resistant strains, is driving demand for Polymixin B ointments in both clinical and retail pharmacy settings. As healthcare professionals emphasize topical treatments for managing skin infections, the ointment product type is projected to experience significant growth in the coming years.

Eye Drops :

Polymixin B eye drops are gaining traction within the market, primarily in response to the rising incidence of bacterial conjunctivitis and other ocular infections. This product type is particularly favored for its targeted delivery method, which ensures that the medication is administered directly to the site of infection, promoting faster healing and reduced irritation. The development of preservative-free eye drop formulations is further enhancing the appeal of this delivery method, as it minimizes discomfort and potential adverse reactions for patients. With an increasing emphasis on eye care and the growing awareness of ocular health, the market for Polymixin B eye drops is expected to expand steadily as healthcare providers seek effective therapies for common eye infections.

Cream :

The cream formulation of Polymixin B is gaining popularity, especially for its versatility in treating various dermatological conditions. Creams provide an appropriate consistency for application on various skin types, facilitating better absorption and increased effectiveness. The demand for Polymixin B cream is being spurred by the rising prevalence of skin infections and the growing trend towards self-care and over-the-counter treatment options. Furthermore, advancements in cream formulations that enhance the stability and shelf life of the product are also contributing to their market growth. As the healthcare market continues to evolve towards more patient-centric treatment options, the demand for Polymixin B cream is likely to witness significant growth.

Powder :

Polymixin B powder is utilized primarily for reconstitution into injectable solutions or for topical use. This form offers versatile applications in both hospital and home settings, particularly for patients requiring customized dosing or those with specific formulation preferences. The increasing trend towards personalized medicine and customized treatment regimens is expected to drive demand for Polymixin B powder in the market. Additionally, the shelf stability of powdered forms is a significant advantage, particularly in resource-limited settings where access to refrigeration may be limited. As the market for compounded medications and individualized therapies continues to grow, the powder segment of Polymixin B is likely to see considerable expansion.

By Application

Hospitals :

The hospital application segment represents the largest share in the Polymixin B market, driven by the heightened need for effective antibiotics in clinical settings. Hospitals are often the frontline in the fight against severe infections, especially those caused by multi-drug resistant bacteria. The increasing number of surgical procedures and the rising incidence of hospital-acquired infections (HAIs) further boost the demand for Polymixin B in these settings. Additionally, the growing awareness and implementation of infection control measures in hospitals are necessitating the use of potent antibiotics like Polymixin B. As healthcare systems worldwide continue to address the challenges posed by antibiotic resistance, hospitals will remain a critical application area for Polymixin B products.

Clinics :

The clinic application segment for Polymixin B is gradually expanding, fueled by the increasing prevalence of outpatient care and a shift towards decentralized healthcare models. Clinics offer a more accessible setting for patients seeking treatment for infections, particularly mild to moderate cases that do not require hospitalization. The rise of walk-in clinics and urgent care centers is facilitating the availability of Polymixin B, allowing for timely intervention and management of infections. Moreover, the focus on preventive care and early treatment in clinics complements the demand for effective antibiotics like Polymixin B. As healthcare delivery continues to evolve, the clinic application segment is poised for steady growth.

Retail Pharmacies :

The retail pharmacy application segment is witnessing significant growth, primarily due to the increasing consumer preference for self-medication and over-the-counter treatments. Retail pharmacies serve as convenient points for patients to access Polymixin B products without the need for a prescription. The growing trend towards health consciousness among consumers has led to an increase in the purchase of topical and oral antibiotics, including Polymixin B. Furthermore, the ongoing expansion of retail pharmacy chains and their ability to stock a wide range of pharmaceutical products are enhancing the accessibility of Polymixin B formulations. As consumers increasingly seek quick and effective solutions for infections, the retail pharmacy segment is expected to flourish.

Online Pharmacies :

The rise of e-commerce has significantly transformed the way pharmaceuticals, including Polymixin B, are distributed and accessed by consumers. Online pharmacies are becoming increasingly popular due to their convenience, allowing patients to order medications from the comfort of their homes. This trend has been further accelerated by the recent global pandemic, which highlighted the importance of remote access to healthcare services. Online platforms provide an extensive selection of Polymixin B formulations, often at competitive prices, making it an appealing option for consumers. Additionally, the ability to offer discreet purchasing options for sensitive conditions enhances the attractiveness of online pharmacies. As the digital landscape continues to evolve, the online pharmacy application segment is anticipated to experience robust growth.

Others :

The other application segment encompasses various alternative settings where Polymixin B may be utilized, such as veterinary applications and specialized clinics focusing on niche therapeutic areas. As awareness surrounding antibiotic resistance grows, there is an increasing recognition of the potential applications of Polymixin B beyond human medicine. Veterinary medicine, in particular, presents a burgeoning market for Polymixin B as it is often used to treat infections in animals. Additionally, specialized clinics dealing with chronic wounds or complex infections may also incorporate Polymixin B into their treatment protocols. As research continues to explore the versatility of Polymixin B, this segment is likely to see incremental growth.

By Distribution Channel

Online Stores :

The increasing proliferation of online stores represents a significant distribution channel for Polymixin B products, particularly in a post-COVID-19 world where digital transactions have become the norm. The convenience of ordering medications online from reputable pharmacies enhances access for consumers, especially those in remote areas or with limited mobility. Online platforms often provide detailed information about the products, including usage instructions and customer reviews, which aids patients in making informed decisions. The ability to provide home delivery further amplifies the appeal of this distribution method, especially for individuals seeking privacy in purchasing medications for sensitive conditions. As the trend towards e-commerce continues to rise, online stores are set to play an increasingly important role in the distribution of Polymixin B.

Supermarkets/Hypermarkets :

Supermarkets and hypermarkets are emerging as viable distribution channels for Polymixin B, particularly in regions where consumers prefer one-stop shopping for their healthcare needs. These establishments often carry a wide array of healthcare products, including Polymixin B formulations in over-the-counter sections. The strategic placement of these products within such stores allows for greater visibility and accessibility, encouraging consumers to consider Polymixin B as a treatment option for infections. Additionally, promotional campaigns and discounts frequently offered by supermarkets can drive impulse purchases of health-related products. As consumer shopping habits evolve towards convenience and variety, supermarkets and hypermarkets are expected to remain integral to Polymixin B's distribution landscape.

Specialty Stores :

Specialty stores, particularly those focused on health and wellness, are increasingly contributing to the distribution of Polymixin B products. These stores typically offer a curated selection of healthcare items, including niche formulations of Polymixin B that may not be available in standard pharmacies. The knowledgeable staff in specialty stores often provide personalized recommendations to consumers, enhancing the shopping experience and ensuring that patients find the most suitable products for their needs. As consumers become more health-conscious and seek targeted solutions for infections, specialty stores are expected to play a vital role in the Polymixin B distribution network.

Drug Stores :

Drug stores are established distribution channels for Polymixin B, facilitating access through traditional brick-and-mortar locations. The presence of licensed pharmacists in drug stores is crucial, as they offer guidance and consultation to consumers regarding the appropriate use of Polymixin B products. With a focus on prescription and over-the-counter medications, drug stores remain a reliable source for healthcare needs, including the procurement of Polymixin B formulations. The integration of drug stores into communities allows for convenient access, particularly for patients who require ongoing treatment for infections. As healthcare continues to emphasize accessibility, drug stores are likely to maintain their importance in the Polymixin B distribution landscape.

Others :

The "Others" distribution channel segment includes various non-traditional avenues for distributing Polymixin B, such as direct sales from manufacturers, home healthcare services, and institutional pharmacies. As healthcare providers increasingly adopt integrated care models, direct sales and institutional pharmacies are becoming essential for ensuring that hospitals and clinics have immediate access to critical medications like Polymixin B. Furthermore, the emergence of home healthcare services, particularly in response to the aging population, is creating new avenues for distributing Polymixin B formulations for at-home treatments. As healthcare continues to evolve, these alternative distribution channels will play an increasingly significant role in the accessibility of Polymixin B products.

By Ingredient Type

Polymixin B Sulfate :

Polymixin B Sulfate is one of the primary ingredient types in the Polymixin B market, widely utilized for its potent antibacterial properties. This ingredient is particularly effective against Gram-negative bacteria, including Pseudomonas aeruginosa, making it a critical option for treating infections that are resistant to standard antibiotics. The availability of Polymixin B Sulfate in various formulations, including injections and topical applications, enhances its usability in diverse clinical settings. As the prevalence of multidrug-resistant bacteria continues to rise, the demand for Polymixin B Sulfate is expected to grow significantly. Moreover, ongoing research aimed at optimizing its formulation for improved efficacy and safety profiles may further solidify its position in the market.

Polymixin B Hydrochloride :

Polymixin B Hydrochloride serves as another crucial ingredient type in the Polymixin B market, known for its effectiveness in treating a range of bacterial infections. This ingredient is often formulated in injectable solutions and is particularly useful in hospital settings where rapid intervention is necessary. The unique properties of Polymixin B Hydrochloride allow for effective penetration into bacterial cell membranes, thus enhancing its antibacterial activity. With the growing recognition of the threat posed by antibiotic-resistant infections, the demand for Polymixin B Hydrochloride is likely to increase. Furthermore, manufacturers are focusing on developing advanced formulations that leverage the benefits of this ingredient, contributing to its anticipated growth within the market.

By Region

The North American region holds a dominant position in the Polymixin B market, accounting for approximately 35% of the global market share. This is primarily attributed to the well-established healthcare infrastructure, high prevalence of multi-drug resistant infections, and significant investment in research and development activities. The increasing awareness about antibiotic resistance among healthcare providers and patients is also driving the demand for effective treatment options like Polymixin B. Moreover, the rise of healthcare outsourcing and the growing trend towards personalized medicine are expected to further bolster market growth in North America. The region is projected to maintain a CAGR of around 5.5% during the forecast period, driven by continuous innovations in Polymixin B formulations and expanded distribution channels.

In Europe, the Polymixin B market is expected to grow steadily, driven by an increasing focus on combating antibiotic resistance and improving infection control measures in healthcare settings. The European market is projected to account for around 30% of the global share, with countries such as Germany, France, and the UK leading in demand. The implementation of stringent regulations regarding antibiotic prescriptions and the growing trend towards outpatient care are further enhancing the market landscape. As healthcare providers in Europe seek effective therapeutic options for managing infections, the market for Polymixin B is anticipated to witness a CAGR of approximately 4.8% over the forecast period.

Opportunities

The Polymixin B market presents numerous opportunities for growth, particularly in response to the escalating threat of antibiotic resistance. This has prompted pharmaceutical companies and research institutions to invest heavily in the development of new formulations and delivery methods that enhance the efficacy of Polymixin B. Moreover, the increasing acceptance of telemedicine and online consultations is facilitating easier access to antibiotic therapies for patients, particularly those in remote areas. As patients become more health-conscious and proactive about managing infections, there is a growing demand for effective and easily accessible treatment options like Polymixin B. Furthermore, the expansion of healthcare infrastructure in emerging markets offers significant prospects for introducing Polymixin B products, thus promoting global market penetration.

In addition, collaborations and partnerships between pharmaceutical companies, healthcare providers, and research institutions are expected to foster innovation and expedite the development of novel Polymixin B formulations. There is also a rising trend towards personalized medicine, which could lead to the creation of customized Polymixin B therapies tailored to individual patient needs. The potential for expanding applications of Polymixin B to veterinary medicine further opens new avenues for growth. As stakeholders continue to prioritize patient outcomes and effective infection management, opportunities for Polymixin B are poised to expand significantly in the coming years.

Threats

Despite the promising growth prospects, the Polymixin B market faces several threats that could hinder its development. One of the primary challenges is the increasing regulatory scrutiny surrounding antibiotic use, as governments and health organizations implement stricter guidelines to combat antibiotic resistance. These regulations can lead to restrictions on the prescription and usage of Polymixin B, thereby impacting market demand. Additionally, competition from alternative antibiotics and emerging therapies may pose a threat to the market share of Polymixin B, as healthcare providers may opt for newer agents that promise fewer side effects and greater efficacy. Furthermore, public perception surrounding the safety and effectiveness of Polymixin B could influence prescribing practices, particularly in light of ongoing concerns about adverse events related to antibiotic use.

Another significant threat is the potential for supply chain disruptions, particularly in the context of global challenges such as pandemics or geopolitical tensions. Any disruptions in the production or distribution of Polymixin B could lead to shortages, ultimately compromising patient care. Moreover, the ongoing challenge of antibiotic resistance itself presents a dual threat; while it drives demand for effective treatments, it also complicates the clinical landscape, as increasingly resistant strains may render traditional therapies ineffective. As a result, stakeholders in the Polymixin B market must remain vigilant and adaptable to navigate these complex challenges effectively.

Competitor Outlook

• Fresenius Kabi AG
• Teva Pharmaceutical Industries Ltd.
• Par Pharmaceutical Companies, Inc.
• Hikma Pharmaceuticals PLC
• Apotex Inc.
• Pfizer Inc.
• Mylan N.V.
• Baxter International Inc.
• Zydus Cadila
• Shionogi & Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Amgen Inc.
• GlaxoSmithKline plc
• Novartis AG
• AbbVie Inc.

The competitive landscape of the Polymixin B market is characterized by the presence of several key players who are actively involved in the production and distribution of Polymixin B formulations. Companies such as Fresenius Kabi AG and Teva Pharmaceutical Industries Ltd. have established themselves as leaders in the market, leveraging their extensive manufacturing capabilities and distribution networks to ensure the availability of Polymixin B products across various healthcare settings. These companies often engage in strategic collaborations and partnerships to enhance their product offerings and expand their reach in the market. Additionally, with a focus on innovation, many of these players are investing in research and development to create advanced formulations and delivery systems that improve the efficacy and safety profile of Polymixin B.

Moreover, established pharmaceutical giants like Pfizer Inc. and GlaxoSmithKline plc are also contributing to the competitive landscape, bringing in significant resources and expertise in drug development. These companies often capitalize on their existing portfolios and market presence to promote Polymixin B as a viable treatment option for resistant infections. Furthermore, the emergence of generic manufacturers such as Mylan N.V. and Apotex Inc. has intensified competition, leading to increased availability and affordability of Polymixin B formulations. As a result, the market dynamics are evolving, and companies are continually adapting their strategies to maintain a competitive edge.

Key players in the Polymixin B market are not only focused on product development but also on enhancing customer experience through effective marketing strategies and patient education initiatives. Companies are increasingly recognizing the importance of raising awareness about antibiotic resistance and the role of Polymixin B in addressing this critical issue. They are engaging healthcare providers through educational programs, clinical guidelines, and promotional campaigns designed to highlight the efficacy of Polymixin B in managing infections. Additionally, investments in digital marketing and e-commerce platforms are enabling these companies to reach a wider audience, thereby further solidifying their presence in the market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Apotex Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Zydus Cadila
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Fresenius Kabi AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Shionogi & Co., Ltd.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Baxter International Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hikma Pharmaceuticals PLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Par Pharmaceutical Companies, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Polymixin B Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Retail Pharmacies
    • 6.1.4 Online Pharmacies
    • 6.1.5 Others
  • 6.2 Polymixin B Market, By Product Type
    • 6.2.1 Injection
    • 6.2.2 Ointment
    • 6.2.3 Eye Drops
    • 6.2.4 Cream
    • 6.2.5 Powder
  • 6.3 Polymixin B Market, By Ingredient Type
    • 6.3.1 Polymixin B Sulfate
    • 6.3.2 Polymixin B Hydrochloride
  • 6.4 Polymixin B Market, By Distribution Channel
    • 6.4.1 Online Stores
    • 6.4.2 Supermarkets/Hypermarkets
    • 6.4.3 Specialty Stores
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Polymixin B Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Polymixin B market is categorized based on

By Product Type

• Injection
• Ointment
• Eye Drops
• Cream
• Powder

By Application

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

By Distribution Channel

• Online Stores
• Supermarkets/Hypermarkets
• Specialty Stores
• Drug Stores
• Others

By Ingredient Type

• Polymixin B Sulfate
• Polymixin B Hydrochloride

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Fresenius Kabi AG
• Teva Pharmaceutical Industries Ltd.
• Par Pharmaceutical Companies, Inc.
• Hikma Pharmaceuticals PLC
• Apotex Inc.
• Pfizer Inc.
• Mylan N.V.
• Baxter International Inc.
• Zydus Cadila
• Shionogi & Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Amgen Inc.
• GlaxoSmithKline plc
• Novartis AG
• AbbVie Inc.